Clinical Medicine and Hepatology Unit, Campus Bio-Medico University, Rome, Italy.
Medical Oncology Unit, Campus Bio-Medico University, Rome, Italy.
Chemotherapy. 2022;67(3):152-163. doi: 10.1159/000521741. Epub 2021 Dec 31.
Sarcopenia is almost constantly observed in patients with cirrhosis and hepatocellular carcinoma (HCC).
Chronic liver disease represents a unique pathophysiological scenario in which sarcopenia develops and all factors involved in the pathogenesis should be taken into account for an appropriate management of the disease. No properly designed intervention studies on this topic are available and, thus, no effective strategies have been developed for clinical practice. Apart from any targeted intervention, treatment, and optimization of liver disease is crucial.
In patients with cirrhosis and HCC, nutritional support to maintain and restore nutrition status, a targeted use of branched-chain amino acids and a guided physical exercise, should all be an integral part of the multidimensional assessment and tailored interventions.
肝硬化和肝细胞癌(HCC)患者几乎普遍存在肌肉减少症。
慢性肝病代表了一种独特的病理生理情况,在此情况下会发生肌肉减少症,应考虑发病机制中的所有相关因素,以对疾病进行适当的管理。针对这一主题,尚无设计合理的干预研究,因此,尚未为临床实践制定出有效的策略。除了任何有针对性的干预措施外,治疗和优化肝脏疾病也至关重要。
在肝硬化和 HCC 患者中,应将维持和恢复营养状况的营养支持、有针对性地使用支链氨基酸以及指导下的体育锻炼,作为多维评估和针对性干预的组成部分。